These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6141237)

  • 21. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of particulate matter in intravenous solutions using the Coulter counter.
    Blaug SM; Sarabia RE
    Bull Parenter Drug Assoc; 1975; 29(2):74-88. PubMed ID: 1120215
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of acceptance criteria for particulate limits for small-volume parenteral products.
    Tsuji K; Lewis AR
    J Pharm Sci; 1978 Jan; 67(1):50-5. PubMed ID: 619115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of agitation on size distribution of particulate matter in large-volume parenterals.
    Blanchard J; Schwartz JA; Byrne DM
    J Pharm Sci; 1977 Jul; 66(7):935-8. PubMed ID: 886454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Royco 367 small volume sample feeder for estimation of particulate contamination in ampoules [proceedings].
    Davies PJ; Smart JD
    J Pharm Pharmacol; 1979 Dec; 31 Suppl():108P. PubMed ID: 42681
    [No Abstract]   [Full Text] [Related]  

  • 26. Particulate matter in four reconstituted cephalosporin injections.
    Kilarski DJ; Visconti JA; Frank SG
    Am J Hosp Pharm; 1983 Apr; 40(4):619-23. PubMed ID: 6846372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interlaboratory comparison about feasibility of insoluble particulate matter test for injections with reduced test volume in light obscuration method.
    Harazono A; Shibata H; Kiyoshi M; Muto T; Fukuda J; Torisu T; Saitoh S; Nishimura H; Uchiyama S; Ishii-Watabe A
    Biologicals; 2019 Jan; 57():46-49. PubMed ID: 30553568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Particulate contamination in parenterals: current issues.
    Groves MJ
    Boll Chim Farm; 1991 Oct; 130(9):347-54. PubMed ID: 1799429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Particulate contamination in plastic ampoules.
    Oppenheim RC; Gillies IR
    J Pharm Pharmacol; 1986 May; 38(5):344-7. PubMed ID: 2872309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An assessment of techniques for evaluating the physical stability of parenteral emulsions.
    Zhang X; Kirsch LE
    PDA J Pharm Sci Technol; 2003; 57(4):300-15. PubMed ID: 14558703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approaches to reducing subvisible particle counts in lyophilized parenteral formulations.
    Gupta PK; Porembski E; Williams NA
    J Pharm Sci Technol; 1994; 48(1):30-7. PubMed ID: 8004415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new coincidence model for single particle counters, Part I: Theory and experimental verification.
    Knapp JZ; Abramson LR
    J Pharm Sci Technol; 1994; 48(3):110-34. PubMed ID: 8069513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specification of limits for particulate contamination in pharmaceutical dosage forms.
    Hailey DM; Lea AR; Kendall CE
    J Pharm Pharmacol; 1982 Oct; 34(10):615-20. PubMed ID: 6128382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Particulate contamination of lyophilized amphotericin B preparation during reconstitution process.
    Sendo T; Hirakawa M; Makino K; Nakashima K; Kataoka Y; Oishi R
    J Clin Pharm Ther; 2001 Apr; 26(2):87-91. PubMed ID: 11350530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. USP perspectives on particle contamination of injectable products.
    Gallelli JF; Groves MJ
    J Parenter Sci Technol; 1993; 47(6):289-92. PubMed ID: 8120733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative estimation of particulate matter in pharmaceutical preparations intended for intravenous administration.
    Bikhazi AB; Shiatis JA; Haddad AF
    J Pharm Sci; 1977 Feb; 66(2):181-6. PubMed ID: 839413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visible particle limits in small volume parenterals.
    Leelarasamee N; Howard SA; Baldwin HJ
    J Parenter Drug Assoc; 1980; 34(3):167-74. PubMed ID: 6901772
    [No Abstract]   [Full Text] [Related]  

  • 38. Photoinduced particulate matter in a parenteral formulation for bisnafide, an experimental antitumor agent.
    Rubino JT; Chan LL; Walker JT; Segretario J; Everlof JG; Hussain MA
    Pharm Dev Technol; 1999 Aug; 4(3):439-47. PubMed ID: 10434290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential hazard of particulate contamination of cardioplegic solutions.
    Robinson LA; Braimbridge MV; Hearse DJ
    J Thorac Cardiovasc Surg; 1984 Jan; 87(1):48-58. PubMed ID: 6690859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An approach to setting particulate matter standards for small volume parenterals.
    DeLuca PP; Boddapati S; Haack D; Schroeder H
    J Parenter Sci Technol; 1986; 40(1):2-13. PubMed ID: 3701538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.